BERLIN, June 17, 2021 (GLOBE NEWSWIRE) — atai Life Sciences B.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the pricing of its upsized initial public offering in the United States of 15,000,000 common shares at a price to the public of $15.00 per share. All common shares are being offered by atai.


Previous articleDiamond Therapeutics contracts BioPharma Services for Phase 1 clinical trial
Next articlePTSF64 – The First Woman to Take Acid, The Drug Policy Reform Act, and Indigenous Language Extinction